European medicines Agency recommends suspension of Avandia, Avandamet and Avaglim
LONDON, Sept. 23, 2010-The European Medicines Agency today recommended the suspension of the marketing authorisations for the rosiglitazone-containing anti-diabetes medicines Avandia, Avandamet and Avaglim.
A controversial diabetes drug, Avandia may lead to higher risk of heart problems, strokes and deaths in older adults.